Cyclometallated platinum(IV) compounds as promising antitumour agents

Since the discovery of the anticancer activity of cisplatin by Rosenberg, extensive research has been carried out in order to develop new and more efficient platinum-containing drugs. In recent years, platinum(IV) compounds are appealing due to their inertness and high lipophilicity. On the other ha...

Descripción completa

Detalles Bibliográficos
Autor: Crespo Vicente, Margarita Ma.
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2019
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/169108
Acceso en línea:https://hdl.handle.net/2445/169108
Access Level:acceso abierto
Palabra clave:Proteïnes supressores de tumors
Quimioteràpia
Tumor suppressor protein
Chemotherapy
id ES_a8d2a22c08b5ff4bb33bfb74c926f177
oai_identifier_str oai:recercat.cat:2445/169108
network_acronym_str ES
network_name_str España
repository_id_str
spelling Cyclometallated platinum(IV) compounds as promising antitumour agentsCrespo Vicente, Margarita Ma.Proteïnes supressores de tumorsQuimioteràpiaTumor suppressor proteinChemotherapySince the discovery of the anticancer activity of cisplatin by Rosenberg, extensive research has been carried out in order to develop new and more efficient platinum-containing drugs. In recent years, platinum(IV) compounds are appealing due to their inertness and high lipophilicity. On the other hand, interest in organometallic platinum compounds such as cyclometallated platinum(II) compounds is based on their stability and on the fact that the presence of a σ(Pt-C) bond increases the lability of the ligand in trans. In contrast, cyclometallated platinum(IV) compounds which combine the properties imparted by the presence of a platinum(IV) centre and a cyclometallated ligand have received little attention. The aim of this review is to present the results obtained so far for cyclometallated platinum(IV) compounds tested as antitumour agents. These compounds are prepared either by intramolecular oxidative addition from electron-rich platinum precursors and adequate ligands or by intermolecular oxidative addition to previously obtained cyclometallated platinum(II) compounds. Tridentate [C,N,N'] cyclometallated platinum(IV) compounds containing one, two or three carbon donor ligands exhibit a remarkable cytotoxicity, in most cases greater than that of cisplatin, against a panel of human cancer cell lines. In contrast, compounds containing a [C,N] platinacycle are less active. For the most active tridentate [C,N,N'] platinum(IV) compounds studies of DNA interaction, topoisomerase I, IIα, and cathepsin B inhibition and ROS generation are presented.Elsevier B.V.2020202120192020info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersion12 p.application/pdfapplication/pdfhttps://hdl.handle.net/2445/169108Articles publicats en revistes (Química Inorgànica i Orgànica)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésVersió postprint del document publicat a: https://doi.org/10.1016/j.organchem.2018.10.008Journal of Organometallic Chemistry, 2019, vol. 879, p. 15-26https://doi.org/10.1016/j.organchem.2018.10.008cc-by-nc-nd (c) Elsevier B.V., 2019http://creativecommons.org/licenses/by-nc-nd/3.0/esinfo:eu-repo/semantics/openAccessoai:recercat.cat:2445/1691082026-05-29T05:05:01Z
dc.title.none.fl_str_mv Cyclometallated platinum(IV) compounds as promising antitumour agents
title Cyclometallated platinum(IV) compounds as promising antitumour agents
spellingShingle Cyclometallated platinum(IV) compounds as promising antitumour agents
Crespo Vicente, Margarita Ma.
Proteïnes supressores de tumors
Quimioteràpia
Tumor suppressor protein
Chemotherapy
title_short Cyclometallated platinum(IV) compounds as promising antitumour agents
title_full Cyclometallated platinum(IV) compounds as promising antitumour agents
title_fullStr Cyclometallated platinum(IV) compounds as promising antitumour agents
title_full_unstemmed Cyclometallated platinum(IV) compounds as promising antitumour agents
title_sort Cyclometallated platinum(IV) compounds as promising antitumour agents
dc.creator.none.fl_str_mv Crespo Vicente, Margarita Ma.
author Crespo Vicente, Margarita Ma.
author_facet Crespo Vicente, Margarita Ma.
author_role author
dc.subject.none.fl_str_mv Proteïnes supressores de tumors
Quimioteràpia
Tumor suppressor protein
Chemotherapy
topic Proteïnes supressores de tumors
Quimioteràpia
Tumor suppressor protein
Chemotherapy
description Since the discovery of the anticancer activity of cisplatin by Rosenberg, extensive research has been carried out in order to develop new and more efficient platinum-containing drugs. In recent years, platinum(IV) compounds are appealing due to their inertness and high lipophilicity. On the other hand, interest in organometallic platinum compounds such as cyclometallated platinum(II) compounds is based on their stability and on the fact that the presence of a σ(Pt-C) bond increases the lability of the ligand in trans. In contrast, cyclometallated platinum(IV) compounds which combine the properties imparted by the presence of a platinum(IV) centre and a cyclometallated ligand have received little attention. The aim of this review is to present the results obtained so far for cyclometallated platinum(IV) compounds tested as antitumour agents. These compounds are prepared either by intramolecular oxidative addition from electron-rich platinum precursors and adequate ligands or by intermolecular oxidative addition to previously obtained cyclometallated platinum(II) compounds. Tridentate [C,N,N'] cyclometallated platinum(IV) compounds containing one, two or three carbon donor ligands exhibit a remarkable cytotoxicity, in most cases greater than that of cisplatin, against a panel of human cancer cell lines. In contrast, compounds containing a [C,N] platinacycle are less active. For the most active tridentate [C,N,N'] platinum(IV) compounds studies of DNA interaction, topoisomerase I, IIα, and cathepsin B inhibition and ROS generation are presented.
publishDate 2019
dc.date.none.fl_str_mv 2019
2020
2020
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/169108
url https://hdl.handle.net/2445/169108
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió postprint del document publicat a: https://doi.org/10.1016/j.organchem.2018.10.008
Journal of Organometallic Chemistry, 2019, vol. 879, p. 15-26
https://doi.org/10.1016/j.organchem.2018.10.008
dc.rights.none.fl_str_mv cc-by-nc-nd (c) Elsevier B.V., 2019
http://creativecommons.org/licenses/by-nc-nd/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by-nc-nd (c) Elsevier B.V., 2019
http://creativecommons.org/licenses/by-nc-nd/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 12 p.
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier B.V.
publisher.none.fl_str_mv Elsevier B.V.
dc.source.none.fl_str_mv Articles publicats en revistes (Química Inorgànica i Orgànica)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415931455733760
score 15,811543

Similares en LA Referencia